Tilray Brands' Prospects Look Bright, Analyst Bullish
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy TLRY?
Source: Fool
- Market Leadership: Tilray continues to dominate the Canadian market, with net revenue from adult-use and medical cannabis rising 8% year-over-year, reinforcing investor confidence through its strong market share across key product categories.
- International Operations Resurgence: The company achieved its highest international cannabis net revenue in history at $24.1 million, a 70% year-over-year increase, indicating the success of its global expansion strategy as international sales now account for 37% of total revenue.
- Beverage Business Growth: Tilray's beverage net revenue jumped 22% year-over-year to $42.6 million, with the acquisition of BrewDog and partnership with Carlsberg accelerating the development of a scaled global beverage platform, enhancing its competitive edge.
- Industry Challenges and Outlook: While analyst Kirk remains optimistic about Tilray's prospects, the company missed consensus revenue estimates in its latest quarter, and ongoing industry volatility presents challenges that investors should carefully consider before betting on significant stock gains.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TLRY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TLRY
Wall Street analysts forecast TLRY stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 7.150
Low
8.50
Averages
9.57
High
10.00
Current: 7.150
Low
8.50
Averages
9.57
High
10.00
About TLRY
Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. It operates through four segments: cannabis operations, beverage operations, distribution operations, and the wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The beverage operations, which encompasses the production, marketing and of beverage products. The distribution operations, which encompasses the purchase and resale of pharmaceutical products to customers. The Wellness products, which encompasses wellness and better-for-you foods and beverages. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, Chowie Wowie and others. It supports over 40 brands in over 20 countries, including cannabis offerings, hemp-based foods and craft beverages.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tilray Reinforces Leadership in Medical Cannabis
- Market Leadership: Tilray holds a leading position in both adult-use and medical markets in Canada, supported by a strong portfolio of brands and deep regulatory expertise, which is expected to drive future growth in the global medical cannabis sector.
- Enhanced Patient Services: Tilray Medical offers over 150 medical cannabis products internationally and has supported more than 400,000 patients, demonstrating its commitment to providing high-quality, reliable medical solutions and further solidifying its market position.
- Science-Driven Innovation: The company focuses on clinical research and physician education to expand access to safe and consistent treatment options, which not only enhances patient treatment experiences but also lays the groundwork for Tilray's continued growth in the global medical market.
- Global Expansion Strategy: Tilray's operations across multiple continents, encompassing pharmaceutical-grade cultivation, production, clinical services, and distribution, ensure the establishment of a patient-centric global platform, reinforcing the company's leadership in the evolving medical cannabis market.
See More
Tilray Brands' Prospects Look Bright, Analyst Bullish
- Market Leadership: Tilray continues to dominate the Canadian market, with net revenue from adult-use and medical cannabis rising 8% year-over-year, reinforcing investor confidence through its strong market share across key product categories.
- International Operations Resurgence: The company achieved its highest international cannabis net revenue in history at $24.1 million, a 70% year-over-year increase, indicating the success of its global expansion strategy as international sales now account for 37% of total revenue.
- Beverage Business Growth: Tilray's beverage net revenue jumped 22% year-over-year to $42.6 million, with the acquisition of BrewDog and partnership with Carlsberg accelerating the development of a scaled global beverage platform, enhancing its competitive edge.
- Industry Challenges and Outlook: While analyst Kirk remains optimistic about Tilray's prospects, the company missed consensus revenue estimates in its latest quarter, and ongoing industry volatility presents challenges that investors should carefully consider before betting on significant stock gains.
See More
Tilray Shares Could Surge Over 40% According to Roth Capital
- Market Leadership: Tilray continues to dominate the Canadian market, with net revenue from adult-use and medical cannabis rising 8% year-over-year, reinforcing investor confidence through its strong market share across key product categories.
- International Business Resurgence: The company achieved its highest international cannabis net revenue in history at $24.1 million, a 70% year-over-year increase, indicating significant potential for global market expansion and revenue diversification.
- Beverage Business Growth: Tilray's beverage net revenue jumped 22% year-over-year to $42.6 million, with the acquisition of BrewDog and partnership with Carlsberg accelerating the development of a scaled global beverage platform, enhancing competitive positioning.
- Ongoing Industry Challenges: Despite positive signs, Tilray faces industry headwinds, having missed consensus revenue estimates in the latest quarter, highlighting the high volatility of the market and necessitating cautious evaluation of future investment risks.
See More
Tilray Brands Faces Significant Challenges in Cannabis Market
- Market Value Collapse: Tilray Brands has seen its stock price plummet by 96% over the past five years, with its market cap dropping from a peak of $20 billion to just $1.5 billion, highlighting the company's struggles in a competitive legal cannabis market.
- Intensified Industry Competition: With approximately 1,000 licensed cannabis companies competing, profit margins are razor-thin, and Tilray faces significant challenges in building brand loyalty due to stringent advertising and packaging restrictions.
- Weak Revenue Growth: Despite a modest 6% increase in net revenue over the past three quarters, Tilray's operating loss remains high at around $47 million, indicating ongoing challenges in achieving profitability.
- Expansion Risks: While Tilray is diversifying into alcohol and international cannabis markets, these ventures are costly and limited in scale, leading to persistent organic growth challenges, compounded by the uncertain timeline for potential U.S. legalization reforms.
See More
Tilray Brands Reports Significant Quarterly Growth
- Revenue Growth: Tilray's net revenue for Q3 fiscal 2026 reached $207 million, an 11% increase year-over-year, and over a four-year period, it has grown by more than 36% compared to $152 million in 2022, demonstrating resilience in a challenging market environment.
- Segment Performance: The beverage segment showed remarkable growth, with sales soaring from $19.6 million to $42.6 million, a 117% increase; however, the core cannabis business only grew by 18%, indicating success in diversifying product lines.
- Market Challenges and Opportunities: Despite significant growth in the beverage sector, the limited prospects for growth in the core cannabis business due to unclear legalization in the U.S. may lead to ongoing market pressures in the future.
- Investment Risk Assessment: Tilray's stock has fallen by 90% over the past four years, reflecting risks associated with weak growth and ongoing losses, making it more suitable for speculators rather than long-term investors, necessitating careful evaluation of its high-risk profile.
See More
Tilray Brands Faces Challenges After BrewDog Acquisition
- Acquisition Update: Tilray acquired UK brewery BrewDog for £33 million ($43.8 million), aiming for a global beverage platform revenue of approximately $500 million annually, although the beer market is currently unfashionable in key regions.
- Stock Price Decline: In March, Tilray's U.S.-listed shares fell nearly 18%, reflecting market concerns over its acquisition and overall business outlook amidst ongoing challenges in both the beer and cannabis industries.
- Analyst Rating Adjustment: TD Cowen's analyst Robert Moskow cut Tilray's price target by 30% to $7 per share while maintaining a buy rating, citing rising aluminum costs as a potential burden on its beer business.
- Industry Struggles: Tilray faces growth challenges in both its cannabis and beer sectors, compounded by high competition and tax rates, leading to investor disappointment regarding its future prospects.
See More
Tilray Reinforces Leadership in Medical Cannabis
- Market Leadership: Tilray holds a leading position in both adult-use and medical markets in Canada, supported by a strong portfolio of brands and deep regulatory expertise, which is expected to drive future growth in the global medical cannabis sector.
- Enhanced Patient Services: Tilray Medical offers over 150 medical cannabis products internationally and has supported more than 400,000 patients, demonstrating its commitment to providing high-quality, reliable medical solutions and further solidifying its market position.
- Science-Driven Innovation: The company focuses on clinical research and physician education to expand access to safe and consistent treatment options, which not only enhances patient treatment experiences but also lays the groundwork for Tilray's continued growth in the global medical market.
- Global Expansion Strategy: Tilray's operations across multiple continents, encompassing pharmaceutical-grade cultivation, production, clinical services, and distribution, ensure the establishment of a patient-centric global platform, reinforcing the company's leadership in the evolving medical cannabis market.
See More
Tilray Brands' Prospects Look Bright, Analyst Bullish
- Market Leadership: Tilray continues to dominate the Canadian market, with net revenue from adult-use and medical cannabis rising 8% year-over-year, reinforcing investor confidence through its strong market share across key product categories.
- International Operations Resurgence: The company achieved its highest international cannabis net revenue in history at $24.1 million, a 70% year-over-year increase, indicating the success of its global expansion strategy as international sales now account for 37% of total revenue.
- Beverage Business Growth: Tilray's beverage net revenue jumped 22% year-over-year to $42.6 million, with the acquisition of BrewDog and partnership with Carlsberg accelerating the development of a scaled global beverage platform, enhancing its competitive edge.
- Industry Challenges and Outlook: While analyst Kirk remains optimistic about Tilray's prospects, the company missed consensus revenue estimates in its latest quarter, and ongoing industry volatility presents challenges that investors should carefully consider before betting on significant stock gains.
See More
Tilray Shares Could Surge Over 40% According to Roth Capital
- Market Leadership: Tilray continues to dominate the Canadian market, with net revenue from adult-use and medical cannabis rising 8% year-over-year, reinforcing investor confidence through its strong market share across key product categories.
- International Business Resurgence: The company achieved its highest international cannabis net revenue in history at $24.1 million, a 70% year-over-year increase, indicating significant potential for global market expansion and revenue diversification.
- Beverage Business Growth: Tilray's beverage net revenue jumped 22% year-over-year to $42.6 million, with the acquisition of BrewDog and partnership with Carlsberg accelerating the development of a scaled global beverage platform, enhancing competitive positioning.
- Ongoing Industry Challenges: Despite positive signs, Tilray faces industry headwinds, having missed consensus revenue estimates in the latest quarter, highlighting the high volatility of the market and necessitating cautious evaluation of future investment risks.
See More
Tilray Brands Faces Significant Challenges in Cannabis Market
- Market Value Collapse: Tilray Brands has seen its stock price plummet by 96% over the past five years, with its market cap dropping from a peak of $20 billion to just $1.5 billion, highlighting the company's struggles in a competitive legal cannabis market.
- Intensified Industry Competition: With approximately 1,000 licensed cannabis companies competing, profit margins are razor-thin, and Tilray faces significant challenges in building brand loyalty due to stringent advertising and packaging restrictions.
- Weak Revenue Growth: Despite a modest 6% increase in net revenue over the past three quarters, Tilray's operating loss remains high at around $47 million, indicating ongoing challenges in achieving profitability.
- Expansion Risks: While Tilray is diversifying into alcohol and international cannabis markets, these ventures are costly and limited in scale, leading to persistent organic growth challenges, compounded by the uncertain timeline for potential U.S. legalization reforms.
See More
Tilray Brands Reports Significant Quarterly Growth
- Revenue Growth: Tilray's net revenue for Q3 fiscal 2026 reached $207 million, an 11% increase year-over-year, and over a four-year period, it has grown by more than 36% compared to $152 million in 2022, demonstrating resilience in a challenging market environment.
- Segment Performance: The beverage segment showed remarkable growth, with sales soaring from $19.6 million to $42.6 million, a 117% increase; however, the core cannabis business only grew by 18%, indicating success in diversifying product lines.
- Market Challenges and Opportunities: Despite significant growth in the beverage sector, the limited prospects for growth in the core cannabis business due to unclear legalization in the U.S. may lead to ongoing market pressures in the future.
- Investment Risk Assessment: Tilray's stock has fallen by 90% over the past four years, reflecting risks associated with weak growth and ongoing losses, making it more suitable for speculators rather than long-term investors, necessitating careful evaluation of its high-risk profile.
See More
Tilray Brands Faces Challenges After BrewDog Acquisition
- Acquisition Update: Tilray acquired UK brewery BrewDog for £33 million ($43.8 million), aiming for a global beverage platform revenue of approximately $500 million annually, although the beer market is currently unfashionable in key regions.
- Stock Price Decline: In March, Tilray's U.S.-listed shares fell nearly 18%, reflecting market concerns over its acquisition and overall business outlook amidst ongoing challenges in both the beer and cannabis industries.
- Analyst Rating Adjustment: TD Cowen's analyst Robert Moskow cut Tilray's price target by 30% to $7 per share while maintaining a buy rating, citing rising aluminum costs as a potential burden on its beer business.
- Industry Struggles: Tilray faces growth challenges in both its cannabis and beer sectors, compounded by high competition and tax rates, leading to investor disappointment regarding its future prospects.
See More
